Form 4: Madrigal Pharmaceuticals' General Counsel Shannon T. Kelley Acquires Shares and Options

Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• On August 15, 2024, Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, acquired 5,215 shares of common stock and stock options for 7,820 shares.
• The common stock was acquired at a price of $0.
• Following the transaction, Kelley directly owns 7,982 shares of common stock.
• The stock options have an exercise price of $244.50 and expire on August 15, 2034.
• The options vest 25% on August 15, 2025, and then 6.25% quarterly thereafter, contingent on continued service.
• The restricted stock units vest 25% annually from August 15, 2025, to August 15, 2028, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be interpreted as a sign of confidence, but it's not overwhelmingly positive or negative.

Positives

• The acquisition of shares and options by a company officer could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the restricted stock units and stock options are contingent on the Reporting Person's continued service with the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view insider transactions as a signal of management's confidence in the company's future performance.

Key Dates